Involvement of the aryl hydrocarbon receptor (AHR) in carcinogenesis has been suggested in many studies. Upregulation of AHR has been reported in some cancer species, and an association between single-nucleotide polymorphisms (SNPs) of AHR and cancer risk or cancer development has also been reported. This evidence suggests the involvement of some specific SNPs in AHR transcriptional regulation in the process of carcinogenesis or cancer development, but there have been no studies to elucidate the mechanism involved. In this study, we identified the transcription factor Nuclear Factor 1-C (NF1C) as a candidate to regulate AHR transcription in a polymorphism-dependent manner. SNP rs10249788 was included in a consensus binding site for NF1C. Our results suggested that NF1C preferred the C allele to the T allele at rs10249788 for binding. Forced expression of NF1C suppressed the activity of the AHR promoter with C at rs10249788 stronger than that with T. Moreover, expression analysis of human uterine endometrial cancer (HEC) specimens showed greater upregulation of AHR and downregulation of NF1C than those of normal endometrium specimens. Sequence analysis showed HEC patients at advanced stages tended to possess T/T alleles more frequently than healthy women. We also demonstrated that NF1C suppressed proliferation, motility and invasion of HEC cells. This function was at least partially mediated by AHR. This study is the first to report that a polymorphism on the AHR regulatory region affected transcriptional regulation of the AHR gene in vitro. Because NF1C is a tumor suppressor, our new insights into AHR deregulation and its polymorphisms could reveal novel mechanisms of genetic susceptibility to cancer.
INTRODUCTION
The aryl hydrocarbon receptor (AHR) is a member of the basic helix-loop-helix period/AHR nuclear translocation/single-minded (bHLH-PAS) protein superfamily that modulates gene transcription in response to xenobiotic compounds such as environmental pollutants.
1,2 AHR signaling is also involved in physiological processes such as proliferation, differentiation, cell cycle arrest and apoptosis independent of exogenous ligands. 3 Very recently, an endogenous ligand or an ingredient, we intake daily from vegetables, was identified to activate AHR. [4] [5] [6] AHR activated by these ligands was reported to modulate immune responses and affect survival and motility of cancer cells. [4] [5] [6] These findings also indicate that AHR functions in multiple ways in response to multiple ligands.
Involvement of the AHR pathway in carcinogenesis has been suggested in some cancers. Constitutively active AHR was reported to induce hepatocarcinogenesis and gastric tumorigenesis. 7, 8 On the other hand, a number of studies indicate that the AHR pathway is involved in anti-proliferative functions. 9, 10 Although the pathological significance remains controversial, increased expression of AHR was reported in several human cancer species including lung, breast and pancreatic cancer. 9, 11, 12 Recently, an association between nucleotide polymorphisms of the AHR gene and cancer risk or cancer development has been studied in lung and breast cancers. [13] [14] [15] [16] [17] [18] These series of studies suggest the involvement of some specific genetic polymorphisms in the mechanism of AHR upregulation in carcinogenesis or cancer development. Among the polymorphisms found in cancer patients, some could be responsible for AHR upregulation. However, there have been no reports on the impact of AHR polymorphisms on AHR expression mechanisms.
Nuclear Factor 1 (NF1) is a transcription factor that was initially identified as a host encoded protein required for the initiation of adenovirus replication. 19 Recently, there has been a growing number of gene regulatory elements in both viral enhancers and cellular genes found to have NF1 binding sites. 20 Several studies have implicated the involvement of an NF1 dysfunction in tumor development and support the idea that a loss in NF1 activity facilitates tumor formation. 21, 22 Most recently, a more direct demonstration showed that NF1C, a member of the NF1 family, was lost during mammary tumor progression, and that NF1C suppressed tumorigenesis and the epithelial-to-mesenchymal transition (EMT) of breast cancer cells. 23 In this study we report that a polymorphism on the AHR regulatory region affects AHR transcription regulated by NF1C in vitro. Because NF1C is a tumor suppressor, our new insights into AHR deregulation and its polymorphism could reveal novel mechanisms of genetic susceptibility to cancer.
RESULTS

Identification of the AHR promoter
For the purpose of studying the impact of single-nucleotide polymorphisms (SNPs) on AHR transcription, we started with identification of the promoter region of AHR transcription. The upstream region of the AHR gene spanning À 1 to À 2376 bp from the transcription start site (TSS) and several truncated constructs were used for the luciferase reporter assay in HeLa cells. A reporter possessing a region spanning À 1 to À 452 bp (pAHR-452) showed similarly high activity to that possessing the À 1 to À 2376 bp (pAHR-2376) region. In contrast, a construct possessing the À 1 to À 122 bp (pAHR-122) region had remarkably lower activity (Figure 1a) .
SNPs on the AHR promoter region Within the promoter region identified, we searched for SNPs in the Japanese population. To avoid the uncertainty and biases, we see when somatic cells are used for analysis, we first chose a complete hydatidiform mole (CHM) to determine SNPs and haplotypes of the AHR regulatory region. 24, 25 Sequencing the region spanning À 1 to À 452 from a total of 50 CHM samples identified two frequent SNPs, rs10249788 (C/T) and rs71010234 (n Â ggggc) ( Table 1) . These two SNPs, rs10249788 and rs71010234, are located at À 130 and À 59 bp from the TSS, respectively. The genomic frequencies of C and T at rs10249788 in CHM were 76.0% and 24.0%, respectively. The most frequent genomic variants found at rs71010234 were 3 Â ggggc (52.0%) and 2 Â ggggc (42.0%) ( Table 1) . We next examined combination patterns of the two SNPs, rs10249788 and rs71010234, to determine haplotypes. Ninety four percent of cases consisted of three patterns, (C, 2 Â ggggc; T, 2 Â ggggc and C, 3 Â ggggc) ( Table 2) . To assess the impact of these polymorphisms on AHR transcription, luciferase reporter genes containing each of the three patterns, (C, 2 Â ggggc; T, 2 Â ggggc and C, 3 Â ggggc) were constructed and compared for their activity. No significant difference was observed between (C, 2 Â ggggc) and (C, 3 Â ggggc). However, a 1.75±0.37-fold higher luciferase activity was observed in (T, 2 Â ggggc) than that of (C, 2 Â ggggc) (Figure 1b ). This data suggested Figure 1 . SNP rs10249788 affected AHR promoter activity. (a) A 5 0 -upstream region of AHR spanning from -2376 to -1 from the TSS was used for the luciferase assay. Truncated forms: À 1417 to À 1, À 452 to À 1 and À 122 to À 1 were also used for the assay. Luciferase activity values were normalized by beta-galactosidase activity values. Results are the mean±s.d. from three independent experiments (**Po0.01). (b) Three different reporter genes possessing regions from -452 to -1 of AHR were used for the luciferase assay. Each of them includes (C, 2 Â ggggc), (C, 3 Â ggggc), or (T, 2 Â ggggc) for two SNPs: (rs10249788, rs71010234), respectively. Luciferase activity values were normalized by betagalactosidase activity values. Results are the mean ± s.d. from three independent experiments (**Po0.01). 
0 . 26, 27 The candidate NF1 binding site on the AHR promoter was 5 0 -A(C/T)GGAATGGAATCCAG-3 0 . The 3 0 half site was different from the conventional consensus sequence, but it was identical to that of the NF1C-binding site on the p53 regulatory region. 28 To study whether NF1 differentially binds to SNP rs10249788, HeLa and TYK-nu cell lines, which possess C/C and T/T alleles at rs10249788 respectively, were examined (Figure 2a ). Both cell lines expressed comparable levels of NF1 proteins (Figure 2b ). For the purpose of investigating the regulation of AHR transcription in cancer cells, we focused on the NF1 subfamily NF1C, which is recognized as a tumor suppressor. 23, 28 Chromatin immunoprecipitation (ChIP) analysis was performed to evaluate NF1C's preference for the C or T allele at rs10249788. NF1C was immunoprecipitated by anti-NF1C antibody in both HeLa and TYKnu cell lines (Figures 2c and d) . Semi-quantitative analysis by realtime PCR revealed that HeLa cells showed a 1.47±0.77-fold higher abundance in the association between NF1C and the AHR regulatory region than that of TYK-nu cells (Figure 2d ). ChIP analysis was also performed on HEC-116 cells, which have C/T alleles. NF1C was transfected into HEC-116 cells, in which NF1C expression was originally absent (Figure 2e ). Cell lysates were immunoprecipitated with anti-NF1C antibody, and precipitated DNA was amplified, subcloned and their sequences were examined. Twenty colonies were picked from each of the five independent experiments and were analyzed for their sequences. As a result, more than five times the number of colonies showed C, relative to those with T at rs10249788 (Figure 2f ). This data also supports the notion that NF1C prefers the C to the T allele for binding. To further confirm the association between NF1C and the AHR regulatory region, an electrophoretic mobility shift assay was performed. A labeled probe with C or T at rs10249788 formed one identical complex with the HeLa nuclear extract, and complexes were super-shifted by the addition of anti-NF1C antibody. The labeled C probe showed a stronger association with protein than the T probe (Supplementary Figure S1 : compare lanes 1 and 6; 7 and 12). The DNA-protein complex was completely competed by six times an excessive amount of unlabeled C probe or T probe (Supplementary Figure S1 : lanes 2 and 3). In contrast, using three times an excessive amount of unlabeled probes, the complex was more efficiently competed with the C probe than that of the T probe (Supplementary Figure S1 : lanes 8 and 9). These data Table 3 . Genotype frequencies of rs10249788 from blood samples (32) 12 ( (f) HEC-116 cells expressing Flag-tagged NF1C were used to immunoprecipitate the NF1C-DNA complex. PCR-amplified products were subcloned, and 20 clones from each of the five independent experiments were examined for their sequences. The number of clones with C and T were shown on the graph.
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suggested that NF1C prefers to associate with the C allele than the T allele at rs10249788.
Effects of NF1C expression on AHR transcription Our data from the ChIP and electrophoretic mobility shift assays suggested that NF1C regulated AHR transcription by direct interaction with the AHR promoter region. HeLa cells, which express detectable amounts of NF1C, were used to examine the effect of NF1C on AHR expression. Successful transfection of HeLa cells with a Flag-tagged NF1C-expressing construct resulted in suppression of AHR expression at mRNA and protein levels (Figures 3a and b) . On the other hand, successful knockdown of NF1C by small interference RNA (siRNA) in HeLa cells resulted in upregulation of AHR expression at mRNA and protein levels (Figures 3c and d) . These data indicate that NF1C dominantly regulates AHR expression at the transcriptional level.
Effects of NF1C expression on AHR promoter activity To examine the impact of SNP rs10249788 on AHR transcriptional regulation by NF1C, a reporter assay was performed. First, HEK293T cells, which do not express NF1C, were transfected with the pAHR-452 reporter gene and a Flag-control or Flag-tagged NF1C expression construct (Figure 4a ). With empty Flag-control vector expression, pAHR-452 with C at rs10249788 showed similar activity to that with T. Flag-tagged NF1C expression on pAHR-452 with C showed less activity of that with T ( Figure 4b ). On the other hand, HeLa cells, which originally express NF1C, were transfected with the pAHR-452 reporter gene and a control siRNA or specific siRNA to knockdown NF1C (siNF1C). Efficient knockdown of NF1C by siNF1C was confirmed by western blotting (Figure 4c ). With a control siRNA, pAHR-452 with C showed less activity than that with T ( Figure 4d ). In contrast, knockdown of NF1C by siNF1C made modest differences on pAHR-452 between C and T at rs10249788 (Figure 4d ).
AHR and NF1C mRNA expression in human uterine endometrial cancer Altered expression of AHR and NF1C were reported in several human cancer species, and our data prompted us to examine AHR and NF1C expression in cancer tissues. 9, 11, 12, 23 AHR was reported to be expressed in the human uterine endometrium and human endometrial cancer (HEC), but there have been no reports on NF1C expression in the uterine endometrium. [29] [30] [31] We chose HEC for expression analysis. 20 normal endometrial tissues and 40 primary HEC tissues, which were from independent cases, were collected for semi-quantitative mRNA analysis by real-time reverse transcription-PCR. AHR mRNA levels were higher in HEC samples than those in normal endometrium samples (Figure 5a ), whereas NF1C mRNA levels were lower in HEC samples than those in normal endometrium samples (Figure 5b ). We could find a similar pattern in protein expression (Figure 5e ). We found no significant differences between early and advanced stages, or between patients with and without metastasis. However, the group with grade 3 endometrioid adenocarcinoma and serous adenocarcinoma showed higher levels of AHR mRNA and less NF1C mRNA than those of the group with grade 1 and grade 2 endometrioid Genotype frequency of SNP rs10249788 in blood and tissue samples of HEC patients Genotypes of rs10249788 were examined in blood samples of 121 HEC patients and were compared with those of the 130 healthy women mentioned above. To examine the genetic preference of T/T in HEC patients, blood samples were classified into T/T and non-T/T groups. There were no differences in genotype frequency between healthy controls and HEC patients (Table 3 ; P ¼ 0.419). We then classified HEC blood samples into early stages (stage I and II) and advanced stages (stage III and IV). HEC samples in early stages showed high similarities in genotype frequency to healthy controls (Table 3 ; P ¼ 0.724). In contrast, we found significant differences in genetic frequencies between healthy controls and HEC patients in advanced stages (Table 3 ; P ¼ 0.015). Normal endometrial tissue and HEC tissue samples were also used to examine rs10249788 genotypes. Their genotypes showed a similar tendency to those of the blood samples (Table 4) .
Effects of NF1C expression on HEC cell properties We next investigated the impact of NF1C expression on two HEC cell lines and on an immortalized endometrial glandular cell line, hEM. 32 HEC cell lines, HHUA and HEC-6 cells possess C/C alleles, and hEM cells possess C/T alleles at rs10249788. At first, we made the cells to transiently express NF1C using adenovirus vectors to examine the effects of NF1C on HEC cells. We used an active mutant type of NF1C, which we called NF1CS, possessing an amino acid substitution of K407E. This mutant was reported to abolish the interaction with proteasome degradation. 23 As with what Nilsson et al. 23 reported, our results also indicated that Ad-NF1CS expressed a higher level of NF1C protein than that of Ad-NF1C in cells (Figure 6a ). Forced expression of NF1CS suppressed cell proliferation, invasion and motility of HEC cells (Figures 6b-d) . However, NF1CS did not affect hEM cells. Considering that hEM cells originally expressed abundant amounts of NF1C, it was conceivable that additional expression of NF1C did not have much of an effect on these cells (Supplementary Figure S2) . Next, successful knockdown of NF1C in HHUA, HEC-6 and hEM cells showed promotion of cell proliferation, invasion and motility (Figures 7b-d) . Clonogenicity on a plain dish was also assessed for HEC cells. Forced NF1CS expression resulted in a decrease, and NF1C knockdown resulted in an increase in the size of HEC cell colonies. (Supplementary Figures S3 and S4) . However, the number of colonies did not vary in both experiments. (Supplementary Figures S3 and S4 ). hEM cells did not form dense colonies (data not shown). Involvement of NF1C in EMT was reported in breast tumor. 23 Our data from marker analysis also suggested that forced expression of NF1C inhibited EMT, and knockdown of NF1C promoted EMT (Figures 6e and 7a ).
AHR expression modulates NF1C function on tumor properties
In the present study, we demonstrated that AHR was transcriptionally regulated by NF1C. Finding a tumor suppressive function of NF1C moved us to examine the impact of AHR on NF1C function. We used double knockdown of NF1C and AHR in the HEC cells. Compared with the single knockdown of NF1C, the double knockdown resulted in suppression of cell proliferation, invasion, motility, colony formation and EMT (Figure 7) . These results suggested that AHR promotes HEC tumor properties, and that NF1C suppresses them by downregulating AHR expression.
DISCUSSION
In this study, we demonstrated that AHR is a direct target of a tumor suppressive transcription factor, NF1C, and that transcription is affected by a SNP in the AHR promoter region. We also showed that knockdown of NF1C in HEC cells enhanced cell proliferation, motility, invasion and EMT (Figure 7) . Moreover, additional knockdown of AHR expression, which was once upregulated by NF1C knockdown, resulted in re-suppression of tumor properties (Figure 7) . These results suggested that suppression of HEC progression by NF1C was at least partially mediated by trans-suppression of AHR expression by NF1C. Although it is controversial whether AHR is tumor promotive or suppressive, some groups have reported that AHR induced an invasive phenotype of tumor cells by induction of an EMT master regulator, SNAI2. 33, 34 Our results suggested that SNAI1 is regulated by AHR, and has a central role in EMT and in an invasive phenotype.
Increased expression of AHR was reported in several human cancer species including lung, breast and pancreatic cancer. 9, 11, 12 In this study, we investigated AHR mRNA expression in HEC. Like other cancer species reported, HEC showed higher levels of AHR mRNA than those of normal endometrium specimens (Figure 5a ). We could not obtain a clear correlation between AHR mRNA levels and tumor stages. This is consistent with a previous study on pancreatic cancer, which reported no differences in AHR mRNA expression between early and advanced stages. 9 This result suggested that upregulation of AHR transcription is a relatively early event in HEC carcinogenesis. 
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We found that NF1C suppressed AHR expression at the transcriptional level (Figures 3 and 4 ). An early characterization of the AHR promoter revealed that a canonical TATA-box was absent and several GC-boxes potentially involved in Sp1 binding were present. 35 Actually, Sp1 binding to the AHR promoter region was reported to upregulate AHR expression. 36 On the other hand, another NF1 member, NF1X, was reported to repress plateletderived growth factor alpha (PDGF-A) transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. 37 Several GC-boxes have been observed adjacent to the NF1-binding site on the AHR promoter. These backgrounds suggest that NF1C suppresses AHR transcription by antagonizing Sp1 occupancy on the AHR promoter.
To obtain evidence that the NF1C/ AHR pathway is involved in carcinogenesis in vivo, NF1C mRNA expression was examined in the same HEC and control samples, which were assessed for AHR expression (Figure 5b ). As expected, NF1C expression showed a pattern opposite to that of AHR expression. Expression analysis of breast cancer reported that NF1C expression was lost in the process of tumor progression, and it was a significant factor to estimate prognosis. 23 In our study, we found no significant differences in NF1C mRNA expression between early and advanced stages, or between patients with and without metastasis. However, we found significant differences in AHR and NF1C expression between a group involved with estrogen responsiveness (grade 1 and 2 endometrioid adenocarcinoma) and one involved with estrogen non-responsiveness (grade 3 endometrioid adenocarcinoma and serous adenocarcinoma) ( Figures 5 c and d ). An adverse function of AHR on the estrogen receptor was reported in several studies. 38, 39 NF1 was reported to regulate its target gene by stimulation with estradiol. 40 Our results imply that AHR and NF1C expression could be associated with the estrogen responsiveness of the HEC cells.
Genetic analysis of blood samples from healthy controls and HEC patients showed that patients in advanced stages had more relevance to T/T alleles at rs10249788 than that of other genotypes (Table 3) . Our results suggested that SNP rs10249788 is associated with the progression, but not the initiation of cancer. Considering that we did not find clear differences in AHR mRNA levels between early and advanced stages, and that we could not Abbreviation: HEC, human uterine endometrial cancer.
obtain a significant correlation between AHR mRNA levels and genotypes, transcription of AHR could be regulated by multiple mechanisms involving SNP rs10249788 and NF1C expression ( Figure 5 and data not shown). Increased expression of AHR has been reported in several human cancer species such as lung, breast and pancreatic cancer. 9, 11, 12 Previous reports and our results demonstrated that NF1C is involved in carcinogenesis. 23 Supported by these backgrounds, our data suggests that the NF1C/AHR pathway is involved in the carcinogenesis of multiple cancer species. AHR is widely expressed in mammalian tissues and is known to have multiple functions. [3] [4] [5] [6] 41 NF1C is also expressed in a variety of tissues. 42 These studies and our results suggest that NF1C could also regulate AHR expression to affect physiological reactions to extrinsic stimuli. Future studies should reveal the involvement of this novel regulation of AHR genes in multiple aspects of cellular activity.
MATERIALS AND METHODS
Cell culture
HeLa, TYK-nu, HEC-116, HHUA, HEC-6, hEM and HEK293T cells were grown in DMEM supplemented with 10% fetal bovine serum, penicillin and streptomycin. TYK-nu, HEC-6 and HEC-116 were purchased from the Japanese Collection of Research Bioresources (Tokyo, Japan), and HeLa and HEK293T were purchased from the American Type Culture Collection (Manassas, VA, USA). hEM cells were a kind gift from Dr Satoru Kyo.
32 hEM cells originated from human endometrial glandular cells immortalized using human papillomavirus-16 E6/7 and human telomerase reverse transcriptase. 32 Tissue samples A total of 50 samples of CHM were macroscopically diagnosed as CHM according to the Japan Society of Obstetrics and Gynecology (JSOG) classification. CHMs that were homozygous at all 17 microsatellite loci were used for SNP genotyping. 43 Samples were collected as part of a national collaborative study sponsored by the Japan Association of Obstetrics and Figure 7 . Effects of NF1C and AHR knockdown on HEC cell properties. (a) Protein expression of NF1C, AHR and EMT markers (VIM, CDH1, SNAI1) in HHUA, HEC-6 and hEM cells, in which NF1C alone or both NF1C and AHR were knocked down. GAPDH was used as an internal control. Lentivirus vectors from PLKO.1-shSCR, -shNF1C or -shAHR were used to make stably knocked-down cells. The top panels in (a) were from longer exposure than those in Figure 6a and e (b-d) The knocked-down cells described above were used to evaluate cell proliferation (b), invasion (c) and motility (d). Results are the mean ± s.d. from three independent experiments (**Po0.01; *Po0.05; n.s., not significant). Real-time reverse transcription-PCR Total RNA from cultured cells was extracted by ISOGEN (Nippon Gene, Tokyo, Japan). complementary DNA was synthesized by ReverTra Ace-a-Kit (Toyobo). Real-time reverse transcription-PCR was carried using SYBR Premic DimerEraser (Takara, Shiga, Japan). Relative expression levels of target genes were calculated using the ddCT method 44 after normalization to those of a housekeeping gene, GAPDH or ACTB. Primers were designed using Primer 3 (ref. 45 ) and their sequences were shown in Supplementary  Table S1 .
Plasmid transfection, adenovirus vector and luciferase assay Several regions upstream of AHR (spanning À 2376 bp, À 1417 bp, À 452 bp and À 122 bp from the TSS) were amplified by PCR and ligated into the pGL-2 luciferase basic vector (Promega, Madison, WI, USA). Cells (3 Â 10 5 ) were transfected with 1 mg of each luciferase reporter and 1 mg of pcDNA3.1-His-LacZ. Forty-eight hours after transfection, cell lysates were collected and assayed using a luciferase assay kit (Promega) and betagalactosidase assay kit (Clontech Laboratories, Mountain View, CA, USA). The open reading frame of NF1C was amplified by PCR and was ligated into the p3 Â FLAG-CMV 7.1 expression vector (Sigma-Aldrich, St. Louis, MO, USA) and pENTR4 (Invitrogen, Carlsbad, CA, USA) vector. Site-directed mutagenesis was performed to generate NF1CS (K407E).
23 pENTR4-NF1CS and pAd/CMV/V5-DEST were used to produce the adenovirus vector Ad-NF1CS (Invitrogen). Ad-NF1CS and the control vector Ad-LacZ were used on cells at a multiplicity of infection 20.
Western blotting
For western blotting, equal amounts of cell lysates were separated on SDSpolyacrylamide gels and transferred onto polyvinylidene difluoride membranes. Primary antibodies used were NF1 (H-300), VIM (V-9), SNAI1 (H-130), CDH1 (H-108), GAPDH (FL-335) (each of them from Santa Cruz Biotechnology, Santa Cruz, CA, USA), FLAG M5 (Sigma-Aldrich), AHR (ab2770) and NF1C (ab89516) (the last two from Abcam, Cambridge, UK). Blots were then incubated with horseradish peroxidase-linked secondary antibodies (Promega) and detected with an enhanced chemiluminescence system.
ChIP assay
A ChIP assay was performed as described elsewhere. 46 The DNA/protein complex was immunoprecipitated using anti-NF1C (Abcam, ab89516) or Histone H3 (Millipore, Billeria, MA, USA) antibodies. Precipitated DNA samples were used to amplify a NF1C binding site or an unrelated site with primers shown in Supplementary Table S2 . PCR products were visualized by agarose gel with ethidium bromide staining, or otherwise, semiquantitated by real-time PCR. The fold enrichment of immunoprecipitated samples was normalized based on 10% input.
Electrophoretic mobility shift assay
An electrophoretic mobility shift assay using HeLa cell nuclear extracts was performed as described elsewhere. 46 Sequences of the probes used are shown in Supplementary Table S3 . To determine whether NF1C was involved in protein-nucleotide complexes, either anti-NF1C (Abcam, ab89516) or anti-SRF (Santa Cruz Biotechnology, sc-335) antibodies were added to the incubation mixture.
Knockdown by siRNA and small hairpin RNA Double-stranded siRNA of NF1C (siNF1C) was purchased from Santa Cruz Biotechnology. Transfection of HeLa with siNF1C was carried out using Oligofectamine reagent (Invitrogen). Transfected cells were assayed after a 48-h culture. We also established HHUA, HEC-6 and hEM cells with stable knockdown of NF1C and AHR by the lentivirus system. 46 Small hairpin RNA (shRNA) target sites and sequences are shown in Supplementary Table S4. shRNA sequences for NF1C were from Sigma-Aldrich (Mission shRNA validated sequence, TRCN0000014711). shRNA sequences for AHR were from Sigma-Aldrich (Mission shRNA validated sequence, TRCN0000245286) or from Dharmacon (siRNA #6 of Smart pool). Both shRNAs showed similar efficiency, and in most cases, shRNA from Sigma-Aldrich was used.
Boyden chamber assay
Cell motility and invasion were evaluated by the Boyden chamber assay as described previously, 47 and 7.5 Â 10 4 of HHUA and HEC-6, 4.0 Â 10 4 of hEM cells were used for analysis.
Clonogenicity on a plain dish
A total of 1 Â 10 3 of HHUA and HEC-6 cells were plated on six-cm dishes, and the number of colonies after 8-12 days culture was examined.
Statistics
Data are represented as the means±s.d.. Reporter assay data were analyzed with a Student's T-test. Case-control data were analyzed with a Student's T-test, Welch-test or one-sided w 2 -squared test. A value of Po0.05 was considered significant.
